Scancell Holdings Plc Scancell Appoints Head of Business Development (6383L)
07 Settembre 2023 - 8:00AM
UK Regulatory
TIDMSCLP
RNS Number : 6383L
Scancell Holdings Plc
07 September 2023
7 September 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell Appoints Dr Mandeep Sehmi as Head of Business
Development
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
today announces the appointment of Dr Mandeep Sehmi as Head of
Business Development, effective immediately.
Mandeep Sehmi brings more than 10 years of experience in
business development and has previously held roles at leading UK
biotech companies including at Abcam, where she managed and
developed the cancer and metabolism portfolios, Cancer Research
Technology, focussing on antibody out licensing, and Isogenica,
where she was involved in deals for their antibody platform,
including a multi-target deal with BioNTech. Mandeep joins Scancell
from ImaginAb where she held the role of Director of Business
Development and worked on a number of out-licensing opportunities
for their lead asset with biotech and pharma in Immuno-oncology for
cell therapies, vaccines and therapeutic antibodies. She holds a
PhD in Cell and Molecular Biology and a Master's degree in
Molecular Pathology and Toxicology from the University of
Leicester, UK.
Prof Lindy Durrant, Chief Executive Officer of Scancell ,
commented: "The appointment of Mandeep is an exciting development
for Scancell as we continue to expand our commercial capabilities.
As communicated at the time of the recent business update , our
strategic focus is on the continued development of the Company's
two lead clinical assets SCIB1 and Modi-1. The value of our
antibody platform, however, remains a powerful asset in enabling us
to generate revenue through high value licence agreements and
Mandeep, with her extensive network and business development
experience in the antibody sector, will be invaluable as the
Company continues to pursue attractive commercialisation avenues
for our therapeutic assets. We welcome Mandeep to the team and look
forward to working with her as we strive to bring innovative
medicines to patients while maximising value for our
shareholders."
Dr Mandeep Sehmi, Head of Business Development at Scancell,
added: "Scancell's innovative cancer vaccines and antibodies have
the potential to make a real difference in the treatment of cancer.
The commercial licence agreement signed with Genmab , a leader in
the field of antibody therapies for cancer, provides strong
validation of the potential of our proprietary antibody platform
and I am looking forward to joining the team to realise the
commercial potential of these therapies for the benefit of
patients."
-ENDS-
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLFMBTMTMMTTJ
(END) Dow Jones Newswires
September 07, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Apr 2023 a Apr 2024
